HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Submit a response Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adhikari, N Articles by Menzies, R Search for Related Content PubMed PubMed Citation Articles by Adhikari, N Articles by Menzies, R

Community-based tuberculin screening in Montreal: a cost-outcome description.

N Adhikari and R Menzies

McGill University, Montreal, Quebec, Canada.

OBJECTIVES. This study describes the costs and outcomes of community-based tuberculin screening programs conducted between 1987 and 1991 in Montreal, Quebec, Canada. METHODS. Follow-up information was abstracted from hospital records of all reactors detected in tuberculin screening of students in grades 6 and 10, of first-year health professional students, and of workers aged 18 to 25 in a number of workforces. Screening costs were estimated directly from survey records, and follow-up costs were estimated from the annual financial report of the Montreal Chest Hospital for 1989/90. RESULTS. Of 7669 persons tested, 782 (10.2%) had positive results and 757 (9.9%) were referred to a clinic. Of those, 525 (6.8% of the original 7669) reported, 293 (3.8%) were prescribed therapy, and 154 (2.0%) were compliant. In Canadian dollars, screening cost $5.70 per person tested and $56 per tuberculin reactor detected, but follow-up of reactors accounted for 73% of the total program cost of $13,455 to $18,753 per case of tuberculosis prevented. CONCLUSIONS. Because of high rates of patient and provider noncompliance, a tuberculin screening program was much less cost-effective than anticipated. Screening costs must be targeted to the highest risk populations, and compliance with recommendations for preventive therapy must be maximized.

This article has been cited by other articles:

				K. Dasgupta and D. Menzies Cost-effectiveness of tuberculosis control strategies among immigrants and refugees Eur. Respir. J., June 1, 2005; 25(6): 1107 - 1116. [Abstract] [Full Text] [PDF]

				D. Menzies, M.-J. Dion, B. Rabinovitch, S. Mannix, P. Brassard, and K. Schwartzman Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 Months Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 445 - 449. [Abstract] [Full Text] [PDF]

				S. Chang, L. S. M. Wheeler, and K. P. Farrell Public Health Impact of Targeted Tuberculosis Screening in Public Schools Am J Public Health, December 1, 2002; 92(12): 1942 - 1945. [Full Text] [PDF]

				K. SCHWARTZMAN and D. MENZIES Tuberculosis Screening of Immigrants to Low-Prevalence Countries . A Cost-effectiveness Analysis Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): 780 - 789. [Abstract] [Full Text] [PDF]

				D. Menzies, T. N. Tannenbaum, and J. M. FitzGerald Tuberculosis: 10. Prevention Can. Med. Assoc. J., September 1, 1999; 161(6): 717 - 724. [Full Text] [PDF]